Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EBS with free AI briefings, catalyst countdowns, and dilution alerts.

EBS · Emergent BioSolutions Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$175.7M Cash on Hand
CF+ Cash Runway
Follow EBS by email Get an email when EBS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EBS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Raxibacumab
FDA approved Dec 2012 · Raxibacumab
Infections, Bacterial Phase 4 · NCT02339155 Completed
Brincidofovir
FDA approved Jun 2021 · Tembexa
Smallpox Phase 1 · NCT05935917 Completed
Anti-Vector Antibody Infections, Bacterial Phase 4 · NCT02339155 Completed
Vaccination with ACAM2000 Smallpox Vaccine Adverse Reaction Phase 4 · NCT02443623 Completed
Sample Collection Infections, Bacterial Phase 4 · NCT02177721 Not yet recruiting
Hepatitis B Vaccine Healthy Volunteers Phase 3 · NCT01311674 Terminated
BioThrax Anthrax Phase 3 · NCT03877926 Completed
AV7909 Anthrax Phase 3 · NCT03877926 Completed
Zanolimumab T Cell Lymphoma Phase 2/3 · NCT00877656 Completed
ACAM2000 Smallpox Vaccine Adverse Reaction Phase 3 · NCT01158157 Completed
DNA Damage-Inducible Transcript 3 Protein T-cell Lymphoma Phase 2 · NCT00893516 Terminated
Dose of 1.1 x 10^10 CFU (Cohort 3) Typhoid Phase 2 · NCT00679172 Completed
Dose of 5.0 x 10^9 CFU (Cohort 1) Typhoid Phase 2 · NCT00679172 Completed
ACAM2000 Smallpox Vaccine Smallpox Phase 2 · NCT00053482 Completed
Dose of 7.5 x 10^9 CFU (Cohort 2) Typhoid Phase 2 · NCT00679172 Completed
Dose of of 1.7 x 10^10 CFU (Cohort 4) Typhoid Phase 2 · NCT00679172 Completed

Also used in these trials (approved or third-party drugs, not EBS's own candidates): Diphenhydramine Hydrochloride, Adjuvant, Ciprofloxacin, Doxycycline.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EBS holds $175.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EBS files for a raise →

👥 Who Owns EBS

Insiders 5.7% Institutions (256 holders) 91.3% Public and other holders 3%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 4,651,339 9.05% 2026-06-30
Oak Hill Advisors LP Institution (13G, 5%+) 4,014,015 7.81% 2026-09-30
American Century Investment Management, Institution (13G, 5%+) 3,312,329 6.44% 2026-09-30
Dimensional Fund Advisors LP Institution (13G, 5%+) 2,757,158 5.36% 2026-03-31
STATE STREET CORPORATION Institution (13G, 5%+) 2,696,375 5.24% 2025-12-31
Joseph C Papa
President and CEO, Director · +1.78M options
Insider 493,153 0.96% 2026-04-29
Richard S Lindahl
EVP, Chief Financial Officer · +557,346 options
Insider 374,083 0.73% 2026-06-08
Coleen Glessner
EVP, Quality & Ethics, and CPL · +294,447 options
Insider 202,201 0.39% 2026-06-08
Stephanie Duatschek
EVP, CGO
Insider 197,416 0.38% 2026-08-05
William Hartzel
SVP, Bioservices · +259,545 options
Insider 185,558 0.36% 2026-06-08
Simon C Lowry
SVP, R&D, CMO · +147,833 options
Insider 177,914 0.35% 2026-04-29
Jessica Perl
SVP, General Counsel, Corp Sec · +142,647 options
Insider 165,286 0.32% 2026-04-29

Share count 51,415,182 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EBS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EBS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.